Richard A. Mortimer
Principal
Boston
Education
Ph.D., economics, University of California, Berkeley; B.A., economics, the Johns Hopkins University
Summary of Experience
Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has provided economic analyses in numerous antitrust matters involving questions of market power, pricing, and market exclusion and foreclosure in a variety of industries, with a focus on healthcare. He also has provided analyses and expert testimony on behalf of clients in the healthcare industry on litigation and government investigations involving allegations of improper promotion and kickback payments. Dr. Mortimer's experience includes leading analyses of large data sets to assess questions of market definition, class certification, liability, and damages. In addition to work in litigation, Dr. Mortimer also has undertaken research in the area of healthcare policy, and he has authored several public policy studies related to pharmaceutical and general healthcare legislation. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.
Selected Cases
Selected Publishing
-
The Economics of Biosimilar Drugs and New Considerations in Intellectual Property and Antitrust Litigation
Public Domain: The Newsletter of the ABA Section of Antitrust Law’s Intellectual Property Committee, July 2018
2018 -
The Rise of Biosimilars and the Future of Healthcare Intellectual Property
IAM, November/December 2018
2018 -
Can The Life Sciences Industry Bank On Biosimilars?
Law360, April 13, 2016
2016 -
Correlation Or Cause: Brand-Name Drug Prescription Rates
Law360, March 23, 2016
2016 -
The Potential For Litigation In New Era Of Biosimilars
Law360, September 20, 2016
2016Frois C, Mortimer R, White A
-
Updated trends in US brand-name and generic drug competition
Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12
2016Grabowski H, Long G, Mortimer R, Boyo A.
-
Recent Trends in Brand Name and Generic Drug Competition
Journal of Medical Economics, March 2014
2014 -
Recent Average Price Trends for Implantable Medical Devices, 2007-2011
White Paper
2013Long G, Mortimer R, Sanzenbacher G
-
Data Exclusivity for Biologics
Nature Reviews Drug Discovery 10, 15-16 (January 2011) - doi:10.1038/nrd3277
2011 -
Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act
Health Affairs, 2011, 30(11), 2157-2166
2011Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N
-
Implementation of the Biosimilar Pathway: Economic and Policy Issues
Seton Hall Law Review, Book 2, 41:2
2011Grabowski HG, Long G, Mortimer R
-
Data Exclusivity Periods and Next Generation Improvements to Innovator Biologics: Key Issues
Duke University Department of Economics Working Paper, No. 2009-05
2009Grabowski H, Cockburn I, Long G, Mortimer R
-
Data Exclusivity Periods for Biologics: Updating Prior Analyses and Responding to Critiques
Duke University Department of Economics Working Paper, No. 2008-10
2008 -
The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions
White Paper
2007Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S
-
Authorized Generic Drugs, Price Competition, And Consumers’ Welfare
Health Affairs - 26, no. 3 (2007): 790-799
2007Berndt E, Parece A, Tuttle E, Mortimer R, Bhattacharjya A
-
Do Authorized Generic Drugs Deter Paragraph IV Certifications? Recent Evidence
Working Paper: April 17, 2007
2007Berndt E, Mortimer R, Parece A
News
-
August 13, 2018
-
May 22, 2017
-
April 13, 2017
-
November 30, 2016
-
September 22, 2016
-
May 03, 2016
-
March 09, 2016
